Education
About Us
Working with TipRanks
Follow Us
Sofia Heigis Insider Profile
4 Followers
Sofia Heigis, Chief Executive Officer at Oncopeptides AB, holds 263.50K shares in Oncopeptides AB (Ticker: SE:ONCO). Most recently, Sofia Heigis Bought 87,833 shares of Oncopeptides AB on Mar 17, 2026 for an estimated value of kr136.14K.
Sofia Heigis Oncopeptides AB (ONCO)Chief Executive Officer
Oncopeptides AB (ONCO)
Chief Executive Officer
Ranked #82,552 out of 106,487 Corporate Insiders
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-21.60%
Average return per transaction
Time Frame
Compare to
Insider Roles
Chief Executive Officer
Roles that Sofia Heigis holds in companies
Most Profitable Insider Trade
The most profitable trade made by Sofia Heigis
Sofia Heigis's Trading History
List of latest transactions for each holding click on a transaction to see Sofia Heigis's performance on stock
You May Also Like
Sofia Heigis insider profile FAQ
What is the percentage of profitable transactions made by Sofia Heigis?
The percentage of profitable transactions made by Sofia Heigis is 25%.
What is the average return per transaction made by Sofia Heigis?
The average return per transaction made by Sofia Heigis is -21.60%.
What stocks does Sofia Heigis hold?
Sofia Heigis holds: SE:ONCO stocks.
What was Sofia Heigis’s latest transaction?
Sofia Heigis latest transaction was an Informative Buy of kr136.14K.
What was Sofia Heigis's most profitable transaction?
Sofia Heigis’s most profitable transaction was an Informative Buy of SE:ONCO stock on December 2, 2021. The return on the trade was 79.70%.
What is Sofia Heigis's role in Oncopeptides AB?
Sofia Heigis's role in Oncopeptides AB is Chief Executive Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.